ALS and stem cell therapy
ALS takes strength, speech and independence step by step, and current medicines offer limited help. Our approach focuses on supporting neurological function and the factors that may influence progression.
Medically reviewed by:Javier E. Garrido L.MD, MSc
On this page
What is ALS?
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease of the motor neurons in the brain and spinal cord. These nerve cells carry signals to the muscles used for walking, speaking, swallowing and breathing.
As motor neurons weaken and die, the muscles lose those signals and gradually waste. Most people with ALS have no family history of it, and a small share of cases is inherited. ALS develops at a different pace in each person, so careful evaluation and ongoing monitoring matter.

At Regeneration Clinic Panama, we take an individualized approach to your care. Our medical team will review your condition, medical history, and individual needs to help you understand your treatment options.
Book a ConsultationCommon signs and symptoms
Symptoms often start in one limb or in speech and spread over time, and the pattern differs from person to person.
- Weakness in a hand, arm or leg
- Muscle twitching and cramps
- Stiff or tight muscles
- Tripping or dropping things
- Slurred or slow speech
- Trouble chewing or swallowing
- Shortness of breath, especially when lying down
- Fatigue and weight loss
- Sudden laughing or crying that is hard to control
How ALS is usually treated
Today, ALS care aims to slow progression where possible and protect function and quality of life. FDA-approved medicines include riluzole and edaravone, and tofersen for people with a SOD1 gene variant. A multidisciplinary team adds physical, occupational and speech therapy, nutrition support, communication devices and breathing support.
This care matters and can extend life, and no current treatment restores motor neurons that have been lost. Many families keep looking for additional options to discuss with their neurologist.

How stem cell therapy works for ALS
Inflammation in the brain and spinal cord is part of how ALS advances. Mesenchymal stem cells calm this inflammation, release growth factors that support nerve cells and help regulate the immune response around damaged tissue.
We use mesenchymal stem cells from the Wharton’s Jelly of donated umbilical cords, prepared in our laboratory, as part of selected personalized protocols. They are delivered by IV and, in selected cases, by other routes your physician recommends. Mesenchymal stem cells work alongside your existing ALS care and medicines.
Every patient with ALS has a different history and set of needs, so we start with a full evaluation. Your physician reviews your history, symptoms, previous treatments and test results before deciding whether a regenerative protocol is appropriate. When it is, cell therapy becomes one part of a personalized care plan.
Important: cellular therapy is an evolving area of medicine. Outcomes vary, and treatment decisions are made individually after a medical assessment.
What the research says
These studies were published by independent research teams. Their results are separate from our own patient outcomes.
- Source link
A case-control study compared 67 people with ALS who received Wharton’s Jelly mesenchymal stem cells into the spinal fluid with 67 matched people from an international ALS research database.
About a third progressed more slowly after treatment, half were unchanged and a fifth progressed faster, with no serious adverse reactions; the study was not randomized, and the authors work for the center that provides the therapy.
- Source link
A randomized, placebo-controlled phase 3 trial tested the person’s own bone marrow mesenchymal stem cells, modified to release nerve growth factors, in people with ALS.
The treatment was well tolerated and did not meet its main goal of slowing decline overall; a subgroup with milder disease showed a possible benefit, and markers of nerve inflammation in the spinal fluid improved.
- Source link
A meta-analysis pooled 11 early-phase studies with 220 people with ALS who received stem cells, 152 of them mesenchymal stem cells.
Mesenchymal stem cells given into the spinal fluid appeared to slow functional decline for a limited time, while breathing capacity continued to decline in every group.
Research in ALS is early: most studies are small, the largest randomized trial missed its main goal, and the benefits seen so far tend to be modest and temporary.
Who may consider this
A personalized evaluation may be right for you if you:
- Have a confirmed ALS diagnosis from a neurologist
- Are in an earlier stage, with breathing and swallowing your physician considers stable
- Want to add a supportive option to the care you already receive
- Can travel to Panama City with a companion
- Are ready to share medical records, breathing tests and function scores for a full review
Our medical team decides suitability after reviewing each case.
What to expect
Before Treatment
Our team reviews your medical history and diagnostic information. We may recommend extra tests to understand your current health and whether you may be a candidate.
During Your Stay
If you are eligible, our medical team guides you through each stage of treatment and provides clinical support throughout.
After Treatment
We follow up at 1, 3, 6, 9 and 12 months after treatment and adjust your plan as needed.

Schedule a personalized consultation to discuss your medical history, treatment goals, and potential care options.
Book a ConsultationRelated articles
Real Patients. Real Results.
Patient stories share individual experiences. Results vary, and no outcome is promised.


- Takes less than 2 minutes
- No commitment
- Takes less than 2 minutes
- No commitment
Your questions
Read Full FAQAnswers about safety, cost and what to expect.
No therapy today can stop ALS, and no outcome is promised. Mesenchymal stem cells reduce inflammation and release factors that support nerve cells. Some people in studies progressed more slowly for a time, and results vary from person to person.
No. Mesenchymal stem cell therapy is planned alongside the care you already receive. Our physicians review every medication you take and coordinate with your neurologist, so nothing changes without their input.
Genetic testing helps your neurologist choose treatments such as tofersen for SOD1 ALS. Our physicians review any genetic results as part of your evaluation, and both inherited and sporadic ALS are assessed case by case.
Most research has enrolled people in earlier stages, while breathing and swallowing are still stable. Our physicians review your function scores, breathing tests and history to judge whether you are a candidate.
Mesenchymal stem cells are recognized for medical use in the European Union and Australia, with hundreds of clinical trials underway worldwide. In December 2024, the FDA approved the first mesenchymal stem cell product in the United States, for steroid-refractory acute graft-versus-host disease in children. For other conditions, mesenchymal stem cell therapy is not FDA-approved in the US.
Protocols start at $10,000 USD, and your exact cost depends on your protocol. Treatment is not covered by insurance. Results vary from patient to patient and no outcome is promised.

Still have a question?
Ask us directly. A patient advocate will reply personally.






